TENAX THERAPEUTICS, INC. TENX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
5.22
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$52.6M | — | — | $97.1M |
| 2024 | $0 | -$17.6M | — | — | $92.0M |
| 2023 | — | -$7.7M | — | — | $8.1M |
| 2022 | — | $11.0M | — | -$11.4M | $1.5M |
| 2021 | — | -$32.5M | — | -$10.9M | $4.2M |
| 2020 | — | -$9.9M | — | -$9.3M | $4.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| STAAB THOMAS R II | Chief Financial Officer | 2026-05-11 | Grant | 10,000 | — |
| Rich Stuart | Chief Medical Officer | 2025-12-09 | Buy | 2,500 | $10.22 |
| Rich Stuart | Chief Medical Officer | 2025-12-08 | Buy | 2,500 | $10.10 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.22 (safe)
- Working capital / assets 0.931
- Retained earnings / assets -3.526
- EBIT / assets -0.541
- Equity / liabilities 13.565
Source: SEC EDGAR filings · CIK 0000034956 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.